Price to trailing twelve month operating cash flow for LGND is currently 29.6, higher than 85.74% of US stocks with positive operating cash flow.
With a year-over-year growth in debt of -28.46%, Ligand Pharmaceuticals Inc's debt growth rate surpasses only 11.04% of about US stocks.
Ligand Pharmaceuticals Inc's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is 25.74%, greater than the shareholder yield of 91.09% of stocks in our set.
If you're looking for stocks that are quantitatively similar to Ligand Pharmaceuticals Inc, a group of peers worth examining would be KMPH, AKTS, AXDX, QTWO, and GNMK.
Ligand Pharmaceuticals Incorporated (LGND) Company Bio
Ligand Pharmaceuticals develops therapies that address the unmet medical needs of patients for a range of diseases, including hepatitis, multiple myeloma, muscle wasting, Alzheimers disease, dyslipidemia, diabetes, anemia, epilepsy, focal segmental glomerulosclerosis, and osteoporosis. The company was founded in 1987 and is based in La Jolla, California.
LGND Price Forecast Based on DCF Valuation
DCF Fair Value Target:
The table below illustrates the output of a discounted cash flow forecast using a variety of scenarios for Ligand Pharmaceuticals Inc. To summarize, we found that Ligand Pharmaceuticals Inc ranked in the 24th percentile in terms of potential gain offered. We should note, though, that the most conservative analysis suggests this stock will yield negative results -- and thus may be a potential short opportunity. In terms of the factors that were most noteworthy in this DCF analysis for LGND, they are:
Interest coverage, a measure of earnings relative to interest payments, is 0.26 -- which is good for besting just 24.31% of its peer stocks (US stocks in the Healthcare sector with positive cash flow).
Ligand Pharmaceuticals Inc's weighted average cost of capital (WACC) is 11%; for context, that number is higher than 77.82% of tickers in our DCF set.
Ligand Pharmaceuticals Inc's effective tax rate, as measured by taxes paid relative to net income, is at 0 -- greater than just 0% of US stocks with positive free cash flow.
Terminal Growth Rate in Free Cash Flow
Return Relative to Current Share Price
ABC, SNN, RMD, VIVO, and A can be thought of as valuation peers to LGND, in the sense that they are in the Healthcare sector and have a similar price forecast based on DCF valuation.
Data bridge Market research provides a report in which the Restless Leg Syndrome market drivers and regulations are derived from a famous SWOT analysis technique. We’ve taken up their organization profiles to really understand those key gamers and types.
Ligand Pharmaceuticals ([[LGND]] +5.0%) expects Captisol material sales of ~$200M in 2021 compared to its 2020 full-year expectation of $90M.The company said “recent new contracting with partners and investments in manufacturing capacity have contributed to its Captisol business operating at the highest levels in the history of the technology and...
SAN DIEGO--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces that recent new contracting with partners and investments in manufacturing capacity have contributed to its Captisol business operating at the highest levels in the history of the technology and position Captisol for major growth. Significant new clinical and regulatory developments with Evomela and Kyprolis, among other drugs, are reinforcing the role the proprietary technology serves in enabling important
SAN DIEGO--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces the acquisition of two privately held companies that strengthen and complement its OmniAb® technology platform. Ligand acquired xCella Biosciences, Inc. for $7 million in cash plus potential earnouts, and acquired Taurus Biosciences LLC for $5 million in cash plus non-transferable contingent value rights (CVRs). In addition, Ligand will invest $2.5 million in a new company, Minotaur Therapeutics, which will
SAN DIEGO--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced today that its wholly-owned subsidiary, Pelican Acquisition Sub, Inc. (the “Purchaser”), is commencing a tender offer to purchase all outstanding shares of common stock of Pfenex, Inc. (NYSE American: PFNX) at an offer price of $12.00 per share in cash, plus one non-transferable contractual contingent value right per share representing the right to receive a contingent payment of $2.00 in cash, if a certain